Comparative Pharmacology
Head-to-head clinical analysis: ERYC SPRINKLES versus ERYPED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC SPRINKLES versus ERYPED.
ERYC SPRINKLES vs ERYPED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It is a macrolide antibiotic.
250-500 mg orally every 6 hours (or 333 mg every 8 hours) for adults; maximum 4 g/day.
250–500 mg orally every 6 hours or 500–1000 mg intravenously every 6 hours; maximum 4 g/day.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; prolonged in neonates (2-4 hours) and patients with hepatic impairment.
2-4 hours (prolonged to 4-6 hours in neonates and patients with hepatic impairment); requires q6h dosing for most indications.
Primarily biliary (fecal) elimination (60-80% as unchanged drug) with approximately 5-15% renal excretion of active drug.
Primarily hepatic (biliary excretion of unchanged drug and metabolites); approximately 5% renal excretion as unchanged drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic